The interim data from the Phase 1 study of ELI-002, a cancer immunotherapy, is a significant milestone for Elicio Therapeutics. Positive results may lead to increased investor confidence and a potential rise in the stock price of ELTX. However, the final outcome of the study and regulatory approvals will play a crucial role in determining the long-term impact on the stock price.